|
US10988479B1
|
|
Morphic forms of trilaciclib and methods of manufacture thereof
|
|
WO2021072319A1
|
|
Targeted treatment of cancers with dysregulated fibroblast growth factor receptor signaling
|
|
WO2020257536A1
|
|
Patient selection for enhancement of anti-tumor immunity in cancer patients
|
|
WO2020206035A1
|
|
Treatment of cdk4/6 inhibitor resistant neoplastic disorders
|
|
WO2020206034A1
|
|
Cell cycle inhibiting compounds for the treatment of medical disorders
|
|
WO2020097625A1
|
|
Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations
|
|
WO2020041770A1
|
|
Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one
|
|
US2019374545A1
|
|
Treatment of egfr-driven cancer with fewer side effects
|
|
CA3109385A1
|
|
Benzothiophene estrogen receptor modulators to treat medical disorders
|
|
WO2019222521A1
|
|
Cdk inhibitors for the treatment of neoplastic disorders
|
|
KR20210006365A
|
|
Treatment of cancer with driving tumorigenic mutation
|
|
CA3087570A1
|
|
G1t38 superior dosage regimes
|
|
CN111867592A
|
|
Heterocyclic compounds for the treatment of abnormal cell proliferation
|
|
KR20200020893A
|
|
Shape form of G1T38 and preparation method thereof
|
|
EP3585389A1
|
|
Treatment of egfr-driven cancer with fewer side effects
|
|
CN110461853A
|
|
Benzothiophene estrogenic agents
|
|
MX2019008158A
|
|
Combination therapy for the treatment of cancer.
|
|
AU2017372856A1
|
|
Preservation of immune response during chemotherapy regimens
|
|
CN109789143A
|
|
Antiproliferative based on pyrimidine
|
|
WO2018005863A1
|
|
Pyrimidine-based compounds for the treatment of cancer
|
